// App-Quantinova.ai

1520 : Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched case-control study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study.

Researchers

Presenter

  • Pamela Jean Goodwin

Principal Investigators

  • Martin Tammemagi

  • Matt Moore

  • Ana Elisa Lohmann

  • Frances A. Shepherd

  • Vuk Stambolic

  • Ryan JO Dowling

  • Craig Williams

Medical Centers

  • Brock University, Hamilton, ON, Canada

  • Princess Margaret Cancer Center, University of Toronto, Toronto, ON, CanadaIMS, Rockville, MDLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

  • Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Lung Cancer

  • Chronic obstructive pulmonary disease

Biomarkers

  • High sensitivity C-reactive protein

  • Leptin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved